Prospects for the treatment of diabetic retinopathy: Modulation of endothelial growth factor
https://doi.org/10.14341/2072-0351-5395
Abstract
Диабетическая ретинопатия остается важной проблемой для здравоохранения, поскольку у большинства пациентов, страдающих сахарным диабетом, отмечается ухудшение зрения. Проводимое традиционное лечение (компенсация углеводного обмена и лазерная коагуляция сетчатки) не всегда предотвращает прогрессирующее снижение зрительных функций. С момента выявления участия ростовых факторов в патогенезе ретинопатии начато клиническое применение лекарственных препаратов, блокирующих сосудистый эндотелиальный фактор роста. Комбинированное лечение с применением средств, направленных на блокирование различных звеньев патогенеза, является более эффективным и имеет лучший отдаленный прогноз. Однако до настоящего времени не проведены крупные многоцентровые исследования с целью изучения не только эффективности, но и безопасности такого длительного лечения.
About the Authors
Anatoliy Gennad'evich Kuzmin
Endocrinology Research Centre, Moscow
Olga Mikhailovna Smirnova
Endocrinology Research Centre, Moscow
Dmitriy Valentinovich Lipatov
Endocrinology Research Centre, Moscow
Marina Vladimirovna Shestakova
Endocrinology Research Centre, Moscow
References
1. Fong DS, Aiello L, Gardner TW et al. Diabetic retinopathy. Diabetes Care. 2003;26:226-229.
2. Kinyoun J, Barton F, Fisher M, Hubbard L, Aiello L, Ferris F. Detection of macula edema. Ophthalmoscopy versus photography - Early Treatment Diabetic Retinopathy Study report number 5. The ETDRS Research Group. Ophthalmology. 1989;96:746-750.
3. Leske MC, Chylack LT, Wu SY. The lens opacities case - control study. Risk factors for cataract. Arch Ophthalmol. 1991;109:244-251.
4. Intensive blood-glucose control with sulphonylureas or insulin compare with conventional treatment and risk of complications in patients with type 2 diabetes. Group UKPDRS. Lancet. 1998;352:837-853.
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329:977-986.
6. Flamme I, Frљhlich T, von Reutern M. HRF, a putative basic helix-loophelix- PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev. 1997;63:51-60.
7. Senger DR, Galli SJ, Dvorak AM. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
8. Robert S, Kerbel PhD. Tumor angiogenesis. N Engl J Med. 2008; 358:2039-2049.
9. Ishida S, Usui T, Yamashiro K et al.VEGF165-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483-489.
10. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001; 280:C1358-1366.
11. shida S, Usui T, Yamashiro K et al. VEGF164(165) as the pathophisiological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004;45:368-374.
12. Krzystolilk MG, Afshari MA, Adamis AP et al. Prevention of experimental choreoidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
13. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006;142:660-668.
14. Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontroled open-label clinical study. Ophthalmology. 2006;113:2002-2011.
15. Gragoudas ES, Adamis AP, Cunningham ET et al. Pegaptamib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
16. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
17. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
18. Heier JS, Boyer DS, Ciulla TA et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124:1532-1542.
19. Cunningham ET, Adamis AP, Altaweel M et al. A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endithelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757.
20. Eremina V, Sood m, Haigh J et al. Glomerular-specific alterations of VEGF-A eapression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707-716.
21. Zhu X, Wu S, Dabut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186-193.
22. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-1795.
23. Chou E, Suruma I, Kerrie LW et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: possible explanation for impaired collateral formation in cardiac tissue. Circulation. 2002;105:373-379.
24. Hurwitz H, Saini S. Bevacizumab in treatment of metastatic colorectal cancer: safety and management of adverse events. Semin Oncol. 2006;33:S26-34.
25. Zachary I. Signaling mechanisms mediating vascular endothelial growth factor. Am J Physiol Cell Physiol. 2001;280:C1375-C1386.
26. Marneros AG, Fan J, Yokoyama Y et al. Vascular endothelial gaowth factor expression in retinal pigment epithelium is essential for choriocapillaris development and vision function. Am J Pathol 2005;167:1451-1459.
27. Nishijima K, Yin-Shan N, Zhog L et al. Vascular endothelial growth factor- A is a survival factor for retinal neuros and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Phatol. 2007;171:53-67.
28. Iriyama A, Chen YX, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on the retinal ganglion cell of rat. Br J Ophthalmol. 2007; 91:1230-1233.
29. Inan UU, Avei B, Kusbeci T, Kaderli B et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rat eyes. Invest Ophthalmol. 2007;48:1773-1781.
30. D'Amore PA. Vascular endothelial cell growth factor-antibody just for endothelial cells anymore. Am J Pathol. 2007;171:14-18.
Review
For citations:
Kuzmin A.G., Smirnova O.M., Lipatov D.V., Shestakova M.V. Prospects for the treatment of diabetic retinopathy: Modulation of endothelial growth factor. Diabetes mellitus. 2009;12(2):33-38. (In Russ.) https://doi.org/10.14341/2072-0351-5395
Views:
768
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
